Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

Hepatology (Baltimore, Md.) - 1 Feb 2008

Hou Jinlin, Yin You-Kuan, Xu Daozhen, Tan Deming, Niu Junqi, Zhou Xiaqiu, Wang Yuming, Zhu Limin, He Yongwen, Ren Hong, Wan Mobin, Chen Chengwei, Wu Shanming, Chen Yagang, Xu Jiazhang, Wang Qinhuan, Wei Lai, Chao George, Constance Barbara Fielman, Harb George, Brown Nathaniel A, Jia Jidong

Abstract excerpt

UNLABELLED: Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to Nucleosides

Share to Pyrimidinones

Share to Thymidine

Source

Identifiers

PMID: 18080339
DOI: 10.1002/hep.22075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18080339-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.PMID 18080339Read ↗

Telbivudine versus lamivudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.Semantic proximity Read ↗

HBV genotype B/C and response to lamivudine therapy: a systematic review.Semantic proximity Read ↗

Management of hepatitis B in China.Semantic proximity Read ↗

Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.Semantic proximity Read ↗

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.Semantic proximity Read ↗

240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.Semantic proximity Read ↗

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Lamivudine for patients with chronic hepatitis B and advanced liver disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.